123 related articles for article (PubMed ID: 38051741)
1. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
Gatz SA; Harttrampf AC; Brard C; Bautista F; André N; Abbou S; Rubino J; Rondof W; Deloger M; Rübsam M; Marshall LV; Hübschmann D; Nebchi S; Aerts I; Thebaud E; De Carli E; Defachelles AS; Paoletti X; Godin R; Miah K; Mortimer PGS; Vassal G; Geoerger B
Clin Cancer Res; 2024 Feb; 30(4):741-753. PubMed ID: 38051741
[TBL] [Abstract][Full Text] [Related]
2. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ
Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630
[TBL] [Abstract][Full Text] [Related]
4. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
[TBL] [Abstract][Full Text] [Related]
5. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of WEE1 Is Effective in
Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
[TBL] [Abstract][Full Text] [Related]
7. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cole KA; Ijaz H; Surrey LF; Santi M; Liu X; Minard CG; Maris JM; Voss S; Reid JM; Fox E; Weigel BJ
Cancer; 2023 Jul; 129(14):2245-2255. PubMed ID: 37081608
[TBL] [Abstract][Full Text] [Related]
8. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
[TBL] [Abstract][Full Text] [Related]
10. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Moore KN; Chambers SK; Hamilton EP; Chen LM; Oza AM; Ghamande SA; Konecny GE; Plaxe SC; Spitz DL; Geenen JJJ; Troso-Sandoval TA; Cragun JM; Rodrigo Imedio E; Kumar S; Mugundu GM; Lai Z; Chmielecki J; Jones SF; Spigel DR; Cadoo KA
Clin Cancer Res; 2022 Jan; 28(1):36-44. PubMed ID: 34645648
[TBL] [Abstract][Full Text] [Related]
11. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Cuneo KC; Morgan MA; Sahai V; Schipper MJ; Parsels LA; Parsels JD; Devasia T; Al-Hawaray M; Cho CS; Nathan H; Maybaum J; Zalupski MM; Lawrence TS
J Clin Oncol; 2019 Oct; 37(29):2643-2650. PubMed ID: 31398082
[TBL] [Abstract][Full Text] [Related]
12. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S
Int J Gynecol Cancer; 2023 Aug; 33(8):1208-1214. PubMed ID: 37380217
[TBL] [Abstract][Full Text] [Related]
16. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
Keenan TE; Li T; Vallius T; Guerriero JL; Tayob N; Kochupurakkal B; Davis J; Pastorello R; Tahara RK; Anderson L; Conway J; He MX; Shannon E; Godin RE; Sorger PK; D'Andrea A; Overmoyer B; Winer EP; Mittendorf EA; Van Allen EM; Shapiro GI; Tolaney SM
Clin Cancer Res; 2021 Feb; 27(4):983-991. PubMed ID: 33257427
[TBL] [Abstract][Full Text] [Related]
18. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lheureux S; Cristea MC; Bruce JP; Garg S; Cabanero M; Mantia-Smaldone G; Olawaiye AB; Ellard SL; Weberpals JI; Wahner Hendrickson AE; Fleming GF; Welch S; Dhani NC; Stockley T; Rath P; Karakasis K; Jones GN; Jenkins S; Rodriguez-Canales J; Tracy M; Tan Q; Bowering V; Udagani S; Wang L; Kunos CA; Chen E; Pugh TJ; Oza AM
Lancet; 2021 Jan; 397(10271):281-292. PubMed ID: 33485453
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Leijen S; van Geel RM; Sonke GS; de Jong D; Rosenberg EH; Marchetti S; Pluim D; van Werkhoven E; Rose S; Lee MA; Freshwater T; Beijnen JH; Schellens JH
J Clin Oncol; 2016 Dec; 34(36):4354-4361. PubMed ID: 27998224
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]